ARCT Stock Forecast: Arcturus Therapeutics Holdings, Inc. Price Predictions for 2026-2027
The 13 Wall Street analysts covering Arcturus Therapeutics Holdings, Inc. hold a median 12-month price target of $20 — +168.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 74 of 100 as at 21 Nov 2026 — in the upper half. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Arcturus Therapeutics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (86): Analysts have, on balance, been raising their forecasts.
Growth (21): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ARCT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ARCT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +168.5% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Oct 2026 | Leerink Partners | Maintains | Outperform | $13 → $19 |
| 24 Sept 2026 | BTIG | Maintains | Buy | $23 → $20 |
| 24 Sept 2026 | Citigroup | Upgrade | Buy | $8.00 → $20 |
| 2 July 2026 | Freedom Broker | Initiates | Buy | $27 |
| 18 Mar 2026 | B. Riley Securities | Initiates | Buy | — |
| 5 Mar 2026 | Citigroup | Maintains | Buy | — |
| 4 Mar 2026 | Citigroup | Maintains | Neutral | — |
| 4 Mar 2026 | Piper Sandler | Maintains | Overweight | — |
| 6 Jan 2026 | Citigroup | Maintains | Neutral | — |
| 13 Nov 2025 | Citigroup | Maintains | Neutral | — |
| 11 Nov 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 11 Nov 2025 | Piper Sandler | Maintains | Overweight | — |
| 24 Oct 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 23 Oct 2025 | Citigroup | Downgrade | Neutral | — |
| 23 Oct 2025 | Guggenheim | Downgrade | Neutral | — |
| 23 Oct 2025 | Wells Fargo | Maintains | Overweight | — |
| 22 Oct 2025 | BTIG | Maintains | Buy | — |
| 22 Oct 2025 | Guggenheim | Downgrade | Neutral | — |
| 4 Sept 2025 | HC Wainwright & Co. | Assumes | Buy | $60 |
| 22 Aug 2025 | Leerink Partners | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ARCT.
This page is one stock. Monday covers all of them.
ARCT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ARCT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Arcturus Therapeutics Holdings, Inc. returned +26.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ARCT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 7.2×
- Price / book
- 1.3×
- EV / EBITDA
- —
Cheaper than 15% of US stocks
Cheaper than 61% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −44.4%
- Return on assets
- −23.9%
- Dividend yield
- —
Higher than 23% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Arcturus Therapeutics Holdings, Inc. has a market value of $219.1M and an enterprise value of $56.1M.
Revenue in the twelve months to 30 June 2026: $18.7M. The latest quarter shrank 96.4% year on year.
Net income over the same four quarters: −$93.3M, a −498.2% net margin.
Diluted earnings per share, trailing twelve months: −$3.31.
Free cash flow in the twelve months to 30 June 2026: −$72.8M.
Arcturus Therapeutics Holdings, Inc. employs 106 people — $177K of revenue per employee.
Data provided by Twelve Data
ARCT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ARCT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Arcturus Therapeutics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ARCT
What is the ARCT stock price forecast for 2026-2027?
The 13 Wall Street analysts covering Arcturus Therapeutics Holdings, Inc. have a median 12-month price target of $20, with estimates ranging from $9 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ARCT stock a buy right now?
Of the 13 analysts covering Arcturus Therapeutics Holdings, Inc., 11 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arcturus Therapeutics Holdings, Inc. 74 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ARCT?
As at 21 Nov 2026, Arcturus Therapeutics Holdings, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (86 of 100).
Will ARCT stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts implies +168.5% from the last close, and Ticker Nerd's factor model ranks Arcturus Therapeutics Holdings, Inc. 74 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ARCT stock forecast for 2030?
No analyst covering Arcturus Therapeutics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $40 over the next 12 months.
How has ARCT stock performed over the past year?
Arcturus Therapeutics Holdings, Inc. returned +26.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Arcturus Therapeutics Holdings, Inc. do?
Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics and vaccines for infectious diseases and rare disorders. The company’s core platforms include STARR, a self-amplifying mRNA technology, and LUNAR, a lipid-mediated delivery system designed to help deliver RNA medicines into the body.
About Arcturus Therapeutics Holdings, Inc.
Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics and vaccines for infectious diseases and rare disorders. The company’s core platforms include STARR, a self-amplifying mRNA technology, and LUNAR, a lipid-mediated delivery system designed to help deliver RNA medicines into the body. Its current work centers on liver and respiratory rare diseases, with programs aimed at conditions such as cystic fibrosis and ornithine transcarbamylase deficiency, alongside vaccine candidates for seasonal and pandemic influenza and COVID-19. Arcturus Therapeutics also supports drug substance and drug product manufacturing capabilities as part of its RNA medicine development and commercialization activities. Headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. plays a specialized role in the biotechnology market by advancing RNA-based approaches for both therapeutic and preventive applications.
CEO Mr. Joseph E. Payne M.Sc. · 106 employees · United States · https://arcturusrx.com